These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25472951)

  • 1. Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials.
    Manasanch EE; Korde N; Mailankody S; Tageja N; Bhutani M; Roschewski M; Landgren O
    Haematologica; 2014 Dec; 99(12):1769-71. PubMed ID: 25472951
    [No Abstract]   [Full Text] [Related]  

  • 2. Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting.
    Lonial S
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):82-4. PubMed ID: 27057804
    [No Abstract]   [Full Text] [Related]  

  • 3. New strategies for MGUS and smoldering multiple myeloma.
    Kyle RA
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):507, 509. PubMed ID: 16163229
    [No Abstract]   [Full Text] [Related]  

  • 4. Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
    Fawole A; Abonour R; Stender M; Shatavi S; Gaikazian S; Anderson J; Jaiyesimi I
    Leuk Lymphoma; 2015 Jan; 56(1):34-41. PubMed ID: 24564573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic experiences in multiple myeloma].
    Sonntag R; Favre E; Martz G
    Schweiz Med Wochenschr; 1972 Nov; 102(44):1588-9. PubMed ID: 4566555
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple myeloma: new options, new challenges.
    Lacy MQ
    Mayo Clin Proc; 2006 Jul; 81(7):877-9. PubMed ID: 16835966
    [No Abstract]   [Full Text] [Related]  

  • 7. New agents and approaches in the treatment of multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):151-2. PubMed ID: 16224394
    [No Abstract]   [Full Text] [Related]  

  • 8. Dilemmas in treating smoldering multiple myeloma.
    Ahn IE; Mailankody S; Korde N; Landgren O
    J Clin Oncol; 2015 Jan; 33(1):115-23. PubMed ID: 25422486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma with extramedullary disease.
    Oriol A
    Adv Ther; 2011 Nov; 28 Suppl 7():1-6. PubMed ID: 22105527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on proteasome inhibitors in multiple myeloma.
    Richardson PG
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of asymptomatic myeloma patients.
    Mateos MV
    Expert Rev Hematol; 2015 Feb; 8(1):19-27. PubMed ID: 25363073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of novel agents for patients with newly diagnosed symptomatic multiple myeloma].
    Sunami K
    Rinsho Ketsueki; 2012 Jun; 53(6):580-6. PubMed ID: 22790632
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
    Prince HM; Schenkel B; Mileshkin L
    Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong.
    Bergsagel PL
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):2-3. PubMed ID: 12533738
    [No Abstract]   [Full Text] [Related]  

  • 16. New Treatments and Insights in Multiple Myeloma.
    Faiman B; Noonan K
    ONS Connect; 2016 Jun; 31(6):4 p following 31. PubMed ID: 27430103
    [No Abstract]   [Full Text] [Related]  

  • 17. [Proteasome inhibitors for multiple myeloma].
    Yano H; Iida S
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel agents and the paradigm of continuous treatment in multiple myeloma.
    Palumbo A
    Leuk Res; 2012 Nov; 36 Suppl 1():S1-2. PubMed ID: 23176718
    [No Abstract]   [Full Text] [Related]  

  • 19. Proteasome inhibitors in the treatment of multiple myeloma.
    McBride A; Ryan PY
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.